Active Filter(s):
Details:
Metoject subcutaneous injection pen (methotrexate) works by inhibiting dihydrofolic acid reductase enzyme. It is approved for the treatment of rheumatoid arthritis.
Lead Product(s): Methotrexate
Therapeutic Area: Immunology Product Name: Metoject
Highest Development Status: Approved Product Type: Small molecule
Recipient: Eisai
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2024